Fiala

Peptide library › Brain & nerves

Trofinetide

Also known as Daybue, NNZ-2566

FDA-approved drugBrain & nerves

First approved treatment for Rett syndrome, a rare genetic brain condition; taken by mouth as a liquid.

What people use it for

What Trofinetide does in the body

A modified version of a small fragment of IGF-1 (glypromate). It's thought to reduce brain inflammation and support connections between nerve cells.

Strength of evidence

Moderate: the Phase 3 LAVENDER trial showed modest improvements in symptoms.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2023 as Daybue. Prescription only.

How it's taken

Route: Liquid by mouth or through a feeding tube, twice daily

How long it lasts (half-life): About 1.5 hours

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Trofinetide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Trofinetide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Brain & nerves